Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly Invests In Hearing-Drug Firm Audion

by Lisa M. Jarvis
February 17, 2014 | A version of this story appeared in Volume 92, Issue 7

Eli Lilly & Co. has taken a stake in Audion Therapeutics, a biotech firm with labs in Cambridge, Mass., focused on diseases that affect the ear. As part of the deal, Audion gains the rights to several Lilly compounds intended to treat hearing loss using hair-cell regeneration. Lilly has an option to reacquire the drugs after they have gone through human testing. In the past year, Lilly has brought back in-house two compounds it had licensed out: a diabetes drug from Transition Therapeutics and a migraine treatment from Arteaus Therapeutics.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.